Trials / Conditions / Plexiform Neurofibroma

Plexiform Neurofibroma

20 registered clinical trials studyying Plexiform Neurofibroma — 7 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas NCT06502171	Girish Dhall, MD	Phase 1
Recruiting	Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated NCT07407803	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 3
Recruiting	Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1 NCT06188741	University of Alabama at Birmingham	Phase 2
Not Yet Recruiting	Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosi NCT07024394	Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.	Phase 1 / Phase 2
Recruiting	Neurofibromatosis Type 1 Tumor Early Detection Study NCT06515860	David Miller	—
Recruiting	A Study of Avutometinib for People With Solid Tumor Cancers NCT06104488	Memorial Sloan Kettering Cancer Center	Phase 1
Active Not Recruiting	FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibroma NCT05913037	Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.	Phase 3
Active Not Recruiting	Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and NCT04954001	Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.	Phase 1 / Phase 2
Active Not Recruiting	MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofi NCT03962543	SpringWorks Therapeutics, Inc.	Phase 2
Completed	Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours NCT03326388	Great Ormond Street Hospital for Children NHS Foundation Trust	Phase 1 / Phase 2
Recruiting	A Retrospective Study on Epidemiological Characteristics of Chinese NF1 Patients in Real World (PROMISE) NCT06379230	Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University	—
Active Not Recruiting	Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway. NCT03363217	St. Justine's Hospital	Phase 2
Active Not Recruiting	Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1 NCT03820778	Children's National Research Institute	N/A
Completed	Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas NCT03231306	University of Alabama at Birmingham	Phase 2
Completed	PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1) NCT01800032	UNC Lineberger Comprehensive Cancer Center	—
Completed	Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas NCT01412892	Assistance Publique - Hôpitaux de Paris	Phase 2
Completed	Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibro NCT00727233	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Natural History Study of Patients With Neurofibromatosis Type I NCT00924196	National Cancer Institute (NCI)	—
Completed	Study of PEG-Intron for Plexiform Neurofibromas NCT00396019	University of Pittsburgh	Phase 2
Terminated	AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near NCT00326872	National Cancer Institute (NCI)	Phase 2